NCT Number: NCT00095082
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Novo Nordisk Investigational Site, Helsinki, Finland
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Type 1 diabetes for at least 12 months
- Current treatment with basal-bolus insulin regimen for more than or equal to 3 months
- HbA1c less than or equal to 11.0%
Exclusion criteria
- Proliferative retinopathy or maculopathy
- Recurrent major hypoglycaemia
- Impaired hepatic or renal function
- Cardiac problems or uncontrolled hypertension
Treatment and study plan
insulin glargine
Druginsulin aspart
DrugPrimary outcomes
-
HbA1c
Time frame: after 1 year trial period
Secondary outcomes
-
Adverse events
-
Body weight
-
Hypoglycemia
-
Blood glucose
-
Insulin Treatment Satisfaction
Sponsors and collaborators
Lead sponsor
Novo Nordisk A/S
Industry
Registry information
Official study title
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Nov 1, 2004
- Registry last updated
- Jan 27, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dual Hormone Closed Loop in Type 1 Diabetes
NCT05669547
Autoimmune Diseases, Diabetes
Amersfoort, Netherlands
View Trial DetailsCongenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes
NCT04769167
Autoimmune Diseases, Cardiovascular Abnormalities
St Louis, Missouri, United States
View Trial DetailsPolyTreg Immunotherapy in Islet Transplantation
NCT03444064
Autoimmune Diseases, Diabetes
Edmonton, Alberta, Canada
View Trial DetailsComparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes
NCT05921097
Autoimmune Diseases, Diabetes
Aalborg, Denmark
View Trial Details